← All trials
NCT07178730
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2026
- Primary completion
- Mar 31, 2033
- Completion date
- Mar 31, 2033
- First posted
- Sep 17, 2025
- Last posted
- Sep 17, 2025
- Enrollment
- 765
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- West German Study GroupLead sponsor
- Gilead SciencesCollaborator
- West German Study GroupOfficial
- Ludwig Maximilians UniversityOfficial
- Ev. Hospital Bethesda, MoenchengladbachOfficial
- Kliniken Essen-Mitte, GermanyOfficial
- Ruhr University BochumOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.